Overview

• Syngene's stock hit its lower circuit limit at Rs 675.05 on the BSE after a 10% decline prompted by cautious FY26 projections.
• CEO Peter Bains outlined early-teens underlying revenue growth for FY26, with mid-single-digit growth on a reported basis due to client inventory adjustments.
• CFO Deepak Jain warned of EBITDA margins moderating to the mid-20% range and a potential year-on-year profit after tax decline as new biologics facilities ramp up.
• For FY25, the company reported 4% revenue growth, an 8% profit decline, and Q4 results showing an 11% revenue rise but a 3% profit drop.
• An investor call scheduled for later today aims to address shareholder concerns and provide further clarity on the company's outlook.